BioDesix (BDSX) Q2 2026: Diagnostic Test Volumes Surge 38% as Primary Care Expansion Drives Adoption

2026-08-05 | By EarningsIQ Research

BioDesix delivered a breakout quarter with a 38% surge in diagnostic test volumes, underpinned by rapid primary care adoption and disciplined cost control. Margin expansion and improved salesforce productivity signal scalable growth, while robust clinical evidence continues to unlock new ordering behaviors among providers. Full-year guidance remains unchanged, but management’s measured hiring and capital discipline are central as the company eyes profitability and broader lung nodule market leadership.

Summary

• Primary Care Momentum: Rapid test adoption by general practitioners is unlocking new patient segments and driving volume growth.
• Margin Resilience: Operating leverage and cost discipline are sustaining best-in-class gross margins above 80%.
• Evidence-Driven Expansion: New clinical data is broadening use cases and deepening account penetration across lung nodule management.

Business Overview

BioDesix is a diagnostics company specializing in blood-based biomarker tests for lung disease, with a core focus on early lung cancer detection and risk stratification. The company generates revenue primarily through its diagnostic testing business, which includes Notify CDT and Notify XL2 tests, and a smaller Development Services segment that provides contracted research and test development for biopharma clients. The diagnostics segment accounts for the vast majority of revenue, while the company’s commercial team targets both primary care physicians and pulmonologists to drive test adoption.

Performance Analysis

BioDesix posted robust top-line growth, driven by a 42% increase in diagnostic testing revenue and a 38% rise in total test volumes year over year. The company’s commercial push into primary care is bearing fruit, with primary care test volumes up 133% and now representing 15% of total testing, a share consistent with last quarter but on a much larger base. Pulmonology volumes also grew 31%, reflecting broad-based adoption. Average revenue per test improved, benefiting from expanded payer coverage and enhanced revenue cycle management, both of which are structural rather than one-time gains.

Gross margins reached 82%, a 200 basis point improvement, as operational focus and scale efficiencies offset modest operating expense growth. Operating expenses excluding direct costs rose just 7%, enabling the company to deliver a 37% improvement in net loss and a 56% improvement in adjusted EBITDA loss. Cash management was disciplined, with net cash used in the quarter down 70% from the prior year, and the company exited the quarter with $30 million in cash, bolstered by $6.5 million in at-the-market proceeds.

• Test Volume Acceleration: Fourth consecutive quarter of accelerating growth, with volume up 38% YoY and sequential momentum above seasonal norms.
• Salesforce Productivity Gains: Newer reps are ramping as expected, while tenured reps continue expanding their contribution, supporting scalable growth.
• Development Services Variability: Segment revenue declined due to timing of project completions, though the backlog remains healthy at $8.5 million.

The company’s ability to grow revenue faster than expenses is driving meaningful operating leverage, positioning BioDesix to approach EBITDA profitability as salesforce expansion continues and payer coverage stabilizes.

Executive Commentary

Strategic Positioning

1. Primary Care Market Penetration

The company’s intensified focus on primary care is unlocking a large, previously under-addressed patient segment, with primary care test volumes up 133% year over year. This expansion is strategic, as roughly half of lung nodules are managed by general practitioners. Early adoption of Notify CDT for small nodules is catalyzing broader usage of both Notify CDT and XL2 across the lung nodule continuum, reinforcing a network effect as primary care and pulmonology accounts cross-refer and expand utilization.

2. Clinical Evidence as a Growth Catalyst

BioDesix’s commercial momentum is increasingly underpinned by a growing body of clinical data. The March publication of the largest lung nodule biomarker validation study to date directly accelerated test adoption, especially for small nodules, and subsequent real-world studies presented at the American Thoracic Society meeting further validated both clinical and economic benefits. This evidence-driven approach is deepening account penetration and supporting payer negotiations.

3. Salesforce Expansion and Productivity Curve

The company continues to scale its salesforce, planning to end the year with 120 reps, up from an average of 104 in Q2. Salesforce productivity is improving as newer hires advance along expected curves and tenured reps expand their reach, suggesting that incremental hiring is translating into real volume gains rather than simply inflating costs. Management remains disciplined, maintaining a steady hiring cadence and prioritizing return on investment over rapid expansion.

4. Margin Discipline and Operating Leverage

Gross margins remain above 80%, reflecting both scale benefits and ongoing process improvements. Operating expenses are tightly managed, with only modest increases despite commercial expansion. The company’s approach to cost discipline—growing infrastructure only as needed—positions it to approach profitability even as it invests in growth.

5. Development Services as a Diversification Lever

While a smaller contributor, the Development Services segment offers revenue diversification and exposure to biopharma recovery trends. The $8.5 million contracted backlog and strong ASCO engagement signal future deal flow, though revenue recognition remains lumpy and subject to project timing.

Key Considerations

BioDesix’s Q2 results reflect a disciplined, evidence-driven commercial expansion, with execution strengths in both top-line growth and cost control. The company’s approach is methodical, balancing aggressive market penetration with prudent capital allocation and a focus on sustainable profitability.

Key Considerations:

• Clinical Data as a Differentiator: Ongoing publications and presentations are expanding use cases and driving physician adoption, especially in primary care.
• Salesforce Maturation: Incremental hiring is translating into productivity gains, not just headcount growth, supporting operating leverage.
• Margin Ceiling: With gross margins already above 80%, future improvements will be incremental, shifting focus to volume and cost efficiency.
• Development Services Volatility: Revenue from this segment remains unpredictable, though the pipeline is robust and leverages industry recovery.
• Guideline Updates as a Wildcard: The pending update of ACCP guidelines could be a major catalyst if blood-based biomarkers are included.

Risks

BioDesix faces execution risk in sustaining rapid volume growth as comps toughen in the back half, and the lumpiness of Development Services revenue could create quarterly volatility. Regulatory and guideline updates remain a material uncertainty, as does the pace of payer adoption and reimbursement stability. The company’s measured hiring and cost discipline are strengths, but any misalignment between salesforce expansion and realized productivity could impact the path to profitability.

Forward Outlook

For Q3 2026 and beyond, BioDesix guided to:

• Continued commercial team expansion, targeting approximately 120 sales reps by year-end
• Sustained gross margins at or above 80%

For full-year 2026, management maintained revenue guidance of $108 million to $114 million.

• Salesforce productivity and payer ASP stability are seen as key drivers for hitting the upper end of the range
• Development Services revenue timing remains a variable, but backlog supports future contributions

Management emphasized that continued evidence generation, commercial discipline, and payer engagement are central to achieving sustained profitability and expanding market share in lung diagnostics.

Takeaways

BioDesix’s Q2 performance demonstrates scalable growth and operational discipline, with primary care adoption and clinical validation driving both volume and margin expansion.

• Diagnostic Franchise Strength: The Notify test suite is gaining traction across both primary care and pulmonology, with evidence generation supporting deeper penetration and payer engagement.
• Cost and Capital Efficiency: The company is achieving revenue growth with only modest expense increases, improving operating leverage and cash runway.
• Watch for Guideline Shifts: The upcoming ACCP guideline update and continued clinical publications could catalyze further adoption and payer support, making this a key watchpoint for investors.

Conclusion

BioDesix is executing a disciplined, evidence-driven commercial strategy that is delivering accelerating test volume growth and expanding gross margins. Sustained cost control and measured salesforce expansion are positioning the company to approach profitability, while ongoing clinical validation and potential guideline updates offer additional upside. Investors should monitor commercial productivity, payer developments, and the impact of further clinical data releases as the company builds out its lung diagnostics leadership.

Industry Read-Through

BioDesix’s results signal a broader shift in diagnostics toward primary care engagement and evidence-driven adoption, particularly in early cancer detection. The company’s success in driving volume through clinical publications and targeted commercial expansion underscores the importance of peer-to-peer education and payer alignment in diagnostics commercialization. For the sector, the sustained margin profile and operating leverage achieved by BioDesix highlight the scalability potential for diagnostics players with strong clinical data and disciplined capital allocation. Pending updates to clinical guidelines and payer coverage remain pivotal for broader adoption, with implications for other biomarker and early detection companies targeting large, under-penetrated markets.

BDSX Healthcare Diagnostics Lung Cancer Primary Care Clinical Evidence Margin Expansion Salesforce Productivity